Unlocking more answers
EVALUTION® leverages high quality analytical performance from conventional immunodiagnostic approaches with the unique capability to quantify and monitor binding reactions in real-time. This provides the user with novel, timely and hence highly actionable information.
In the spotlight
ZWIJNAARDE (Ghent), Belgium, August 20, 2019. MyCartis to spin out point-of-need diagnostics business in new company ANTELOPE Dx. New start-up raises 5,1 million EUR.
An investment consortium, with RMM (Rudi Marien) and Saffelberg (Jos Sluys) as lead investors, has invested in the new spin-off Antelope Dx. Together with some high net worth individuals, they have invested 5,1 million EUR in the new diagnostic company that develops innovative technology and applications for point-of-care testing.
Clinical lab performance with the ease-of-use of a pregnancy test
Interview with Jan-Willem Hoste
What is the most exciting aspect of the Antelope technology?
The possibility to bring clinical grade diagnostics into the hands of families, consumers and first-line healthcare professionals. At the moment, the technology is not there to radically change healthcare systems and provide immediate information on your health. This holds for consumers, nurses or doctors (GP’s). For example, you can’t screen yourself for an STI (sexually transmitted infection), nor can a GP immediately test if you need antibiotics or not. Today, it is necessary to send your sample to a centralized clinical lab. Offering that lab-quality analysis at a factor of 1000 of the price, will allow immediate access (near patient testing). The impact of this on the healthcare system and the reduction of the global cost for the society can potentially be immense.
How do you feel about the match with Mycartis?
After the research period, we raised funding at VLAIO and UGent for a two-year incubation track with the goal of building a system, developing a business proposition and raising additional capital to bring the technology to the market. We did an extensive round of pitching for various VCs and angels and found a great match with Mycartis and its investors. We realized that bringing a medical product to the market requires specific expertise, know-how and facilities. Being able to raise both the necessary funding and source these elements in via Mycartis is a win-win situation. Basically we are able to accelerate and increase our chances to be successful with our developments.
“We believe the Antelope technology will connect the dots: affordable and easy to use, yet without compromising on quality”
MyCartis offers an open platform approach allowing partners to co-develop assays or port existing assay products on the platform. MyCartis also supports an OEM approach (DMAT® technology inside) in which case MyCartis’ technology is integrated in partner’s existing or new instruments.